Cargando…

Comprehensive metabolomic characterization of atrial fibrillation

BACKGROUND: Using human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chengcan, Liu, Chunyan, Mei, Di, Yu, Mengjie, Bai, Jian, Bao, Xue, Wang, Min, Fu, Kejia, Yi, Xin, Ge, Weihong, Shen, Jizhong, Peng, Yuzhu, Xu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393302/
https://www.ncbi.nlm.nih.gov/pubmed/36003904
http://dx.doi.org/10.3389/fcvm.2022.911845
_version_ 1784771242657579008
author Lu, Chengcan
Liu, Chunyan
Mei, Di
Yu, Mengjie
Bai, Jian
Bao, Xue
Wang, Min
Fu, Kejia
Yi, Xin
Ge, Weihong
Shen, Jizhong
Peng, Yuzhu
Xu, Wei
author_facet Lu, Chengcan
Liu, Chunyan
Mei, Di
Yu, Mengjie
Bai, Jian
Bao, Xue
Wang, Min
Fu, Kejia
Yi, Xin
Ge, Weihong
Shen, Jizhong
Peng, Yuzhu
Xu, Wei
author_sort Lu, Chengcan
collection PubMed
description BACKGROUND: Using human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages. OBJECTIVES: By investigating disturbed metabolic pathways, we could evaluate the diagnostic value of biomarkers based on metabolomics for different types of AF. METHODS: A cohort of 363 patients was enrolled and divided into a discovery and validation set. Patients underwent an electrocardiogram (ECG) for suspected AF. Groups were divided as follows: healthy individuals (Control), suspected AF (Sus-AF), first diagnosed AF (Fir-AF), paroxysmal AF (Par-AF), persistent AF (Per-AF), and AF causing a cardiogenic ischemic stroke (Car-AF). Serum metabolomic profiles were determined by gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). Metabolomic variables were analyzed with clinical information to identify relevant diagnostic biomarkers. RESULTS: The metabolic disorders were characterized by 16 cross-comparisons. We focused on comparing all of the types of AF (All-AFs) plus Car-AF vs. Control, All-AFs vs. Car-AF, Par-AF vs. Control, and Par-AF vs. Per-AF. Then, 117 and 94 metabolites were identified by GC/MS and LC-QTOF-MS, respectively. The essential altered metabolic pathways during AF progression included D-glutamine and D-glutamate metabolism, glycerophospholipid metabolism, etc. For differential diagnosis, the area under the curve (AUC) of specific metabolomic biomarkers ranged from 0.8237 to 0.9890 during the discovery phase, and the predictive values in the validation cohort were 78.8–90.2%. CONCLUSIONS: Serum metabolomics is a powerful way to identify metabolic disturbances. Differences in small–molecule metabolites may serve as biomarkers for AF onset, progression, and differential diagnosis.
format Online
Article
Text
id pubmed-9393302
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93933022022-08-23 Comprehensive metabolomic characterization of atrial fibrillation Lu, Chengcan Liu, Chunyan Mei, Di Yu, Mengjie Bai, Jian Bao, Xue Wang, Min Fu, Kejia Yi, Xin Ge, Weihong Shen, Jizhong Peng, Yuzhu Xu, Wei Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Using human humoral metabolomic profiling, we can discover the diagnostic biomarkers and pathogenesis of disease. The specific characterization of atrial fibrillation (AF) subtypes with metabolomics may facilitate effective and targeted treatment, especially in early stages. OBJECTIVES: By investigating disturbed metabolic pathways, we could evaluate the diagnostic value of biomarkers based on metabolomics for different types of AF. METHODS: A cohort of 363 patients was enrolled and divided into a discovery and validation set. Patients underwent an electrocardiogram (ECG) for suspected AF. Groups were divided as follows: healthy individuals (Control), suspected AF (Sus-AF), first diagnosed AF (Fir-AF), paroxysmal AF (Par-AF), persistent AF (Per-AF), and AF causing a cardiogenic ischemic stroke (Car-AF). Serum metabolomic profiles were determined by gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). Metabolomic variables were analyzed with clinical information to identify relevant diagnostic biomarkers. RESULTS: The metabolic disorders were characterized by 16 cross-comparisons. We focused on comparing all of the types of AF (All-AFs) plus Car-AF vs. Control, All-AFs vs. Car-AF, Par-AF vs. Control, and Par-AF vs. Per-AF. Then, 117 and 94 metabolites were identified by GC/MS and LC-QTOF-MS, respectively. The essential altered metabolic pathways during AF progression included D-glutamine and D-glutamate metabolism, glycerophospholipid metabolism, etc. For differential diagnosis, the area under the curve (AUC) of specific metabolomic biomarkers ranged from 0.8237 to 0.9890 during the discovery phase, and the predictive values in the validation cohort were 78.8–90.2%. CONCLUSIONS: Serum metabolomics is a powerful way to identify metabolic disturbances. Differences in small–molecule metabolites may serve as biomarkers for AF onset, progression, and differential diagnosis. Frontiers Media S.A. 2022-08-08 /pmc/articles/PMC9393302/ /pubmed/36003904 http://dx.doi.org/10.3389/fcvm.2022.911845 Text en Copyright © 2022 Lu, Liu, Mei, Yu, Bai, Bao, Wang, Fu, Yi, Ge, Shen, Peng and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Lu, Chengcan
Liu, Chunyan
Mei, Di
Yu, Mengjie
Bai, Jian
Bao, Xue
Wang, Min
Fu, Kejia
Yi, Xin
Ge, Weihong
Shen, Jizhong
Peng, Yuzhu
Xu, Wei
Comprehensive metabolomic characterization of atrial fibrillation
title Comprehensive metabolomic characterization of atrial fibrillation
title_full Comprehensive metabolomic characterization of atrial fibrillation
title_fullStr Comprehensive metabolomic characterization of atrial fibrillation
title_full_unstemmed Comprehensive metabolomic characterization of atrial fibrillation
title_short Comprehensive metabolomic characterization of atrial fibrillation
title_sort comprehensive metabolomic characterization of atrial fibrillation
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393302/
https://www.ncbi.nlm.nih.gov/pubmed/36003904
http://dx.doi.org/10.3389/fcvm.2022.911845
work_keys_str_mv AT luchengcan comprehensivemetabolomiccharacterizationofatrialfibrillation
AT liuchunyan comprehensivemetabolomiccharacterizationofatrialfibrillation
AT meidi comprehensivemetabolomiccharacterizationofatrialfibrillation
AT yumengjie comprehensivemetabolomiccharacterizationofatrialfibrillation
AT baijian comprehensivemetabolomiccharacterizationofatrialfibrillation
AT baoxue comprehensivemetabolomiccharacterizationofatrialfibrillation
AT wangmin comprehensivemetabolomiccharacterizationofatrialfibrillation
AT fukejia comprehensivemetabolomiccharacterizationofatrialfibrillation
AT yixin comprehensivemetabolomiccharacterizationofatrialfibrillation
AT geweihong comprehensivemetabolomiccharacterizationofatrialfibrillation
AT shenjizhong comprehensivemetabolomiccharacterizationofatrialfibrillation
AT pengyuzhu comprehensivemetabolomiccharacterizationofatrialfibrillation
AT xuwei comprehensivemetabolomiccharacterizationofatrialfibrillation